6533b826fe1ef96bd12834f9

RESEARCH PRODUCT

A human relevance investigation of PPARα-mediated key events in the hepatocarcinogenic mode of action of propaquizafop in rats

Roy ForsterLysiane RichertChristian StruppWerner BomannFrédéric GervaisFrançois SpéziaPramila Singh

subject

Male0301 basic medicinemedicine.medical_specialtyPeroxisome proliferator-activated receptor010501 environmental sciencesBiologyToxicologyRisk Assessment01 natural sciencesMuscle hypertrophyRats Sprague-Dawley03 medical and health sciencesCytochrome P-450 Enzyme SystemInternal medicinemedicineAnimalsHumansAcyl-CoA oxidasePPAR alphaRelevance (information retrieval)Enzyme inducerReceptorMode of actionCarcinogen0105 earth and related environmental scienceschemistry.chemical_classificationGlutathione PeroxidaseHerbicidesGlutathione peroxidaseLiver NeoplasmsOrgan SizeGeneral MedicineGlutathioneDiet030104 developmental biologyEndocrinologyLiverchemistrybiology.proteinKey (cryptography)Acyl-CoA OxidasePropionatesRats TransgenicNeuroscience

description

Propaquizafop is an herbicide with demonstrated hepatocarcinogenic activity in rodents. A rodent-specific mode of action (MOA) in the liver via activation of peroxisome proliferator-activated receptor α (PPARα) has been postulated based on existing data. Experience with PPARα-inducing pharmaceuticals indicates a lack of human relevance of this MOA. The objective of the present investigation was to evaluate the dependency of early key events leading to liver tumors on PPARα activation in wildtype (WT) compared to PPARα-knockout (KO) rats following 2 weeks exposure to 75, 500 and 1000 ppm propaquizafop in the diet. In WT rats, both WY-14643 (50 mg/kg bw/day) and propaquizafop (dose-dependently) induced marked increases in liver weights, correlating with liver enlargement and hepatocellular hypertrophy, along with increased CYP4A and acyl-CoA oxidase mRNA expression and enzyme activities versus controls, while in KO rats liver weight was mildly increased only at the high dose with minimal microscopic correlates and without any changes in liver peroxisomal or CYP4A activities. In addition, BrdU labeling resulted in higher numbers and density of positive hepatocytes versus controls in WT but not in KO rats, indicating increased mitotic activity and cell proliferation only in WT rats, thus confirming the PPARα-dependency of the biochemical and histological changes in the liver. Based on an assessment of the results of this investigation, together with existing propaquizafop data according to the MOA-Human Relevance Framework, we conclude that liver tumors observed in rodents after dietary administration of propaquizafop do not pose a relevant health risk to humans.

https://doi.org/10.1016/j.toxlet.2018.06.878